Ocular Surgery News U.S. Edition Current Issue

The following articles appeared in the print edition of Ocular Surgery News U.S. Edition.

Table of Contents

• ‘Best Hospitals’ ranking for ophthalmology relies on subjective reputational scores
• Allergan lawsuit against Valeant, Pershing Square cites securities violations
• ASCRS Foundation kicks off mission to end cataract blindness in US
• HARBOR study shows sustained visual gains at 2 years
• MEAD study: Corticosteroid implant improves BCVA at 3 years in eyes with DME
• Positioning important when implanting trabecular micro-bypass stent Jason Bacharach, MD
• Visual field loss and gain comparable at 5 years in open-angle glaucoma patients
• Target specific focal points to optimize refractive outcomes of cataract surgery Uday Devgan, MD
• Intracameral antibiotics for cataract surgery
• Man presents with unilateral intermediate uveitis Fina C. Barouch, MD; Lauren A. Branchini, MD
• Combined phaco-canaloplasty outperforms phaco alone in eyes with OAG
• Diquafosol tetrasodium drops more effective than conventional therapy for LASIK-associated dry eye
• DSAEK similarly safe in eyes with anterior chamber, posterior chamber IOLs
• Epithelial thickness mapping used to guide phototherapeutic keratectomy
• Third-party payer ratings, social media grading sites more meaningful for physicians Richard L. Lindstrom, MD
• Audit: Face-down positioning for macular hole repair unnecessary
• Baseline signs of AMD present in most VIEW 1, VIEW 2 fellow eyes
• Bilateral exams warranted to detect CNV in asymptomatic fellow eyes in patients with neovascular AMD
• Extraocular cytomegalovirus infection linked to increased morbidity, mortality
• Handheld ETDRS device may eliminate need for dedicated test lane
• Macular hole best managed early
• Minimal further treatment for DME needed at year 5 in Protocol I study
• Novel molecule shows promise for future treatment of neovascular AMD
• Novel protein may lead to extended intervals in AMD treatment
• PAT Survey shows treat-and-extend holding steady as preferred strategy
• Real-world treatment of DME yields fewer gains than in trials
• Researcher challenges universal use of AREDS2 formulation
• SD-OCT helps predict response to VEGF therapy in patients with RVO
• SD-OCT predicts progression to geographic atrophy
• Treat-and-extend treatment benefits maintained at 3 years
• Triamcinolone, bevacizumab yield similar VA outcomes in cataract patients with DME
• Visual acuity gains seen in Vibrant study maintained beyond 24 weeks
• Keratolimbal allograft may be used for ocular surface reconstruction in symblephara treatment Marjan Farid, MD
• Physicians need to take care of themselves first Darrell E. White, MD